Ironwood Pharmaceuticals, Inc. (IRWD)
USD 1.24
(-7.84%)
USD 1.24
(-7.84%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 498.3 Million USD | 20.7% |
| 2022 | 412.85 Million USD | 16.03% |
| 2021 | 355.81 Million USD | -21.03% |
| 2020 | 450.57 Million USD | 4.77% |
| 2019 | 430.07 Million USD | 17.41% |
| 2018 | 366.29 Million USD | -7.52% |
| 2017 | 396.09 Million USD | 8.05% |
| 2016 | 366.57 Million USD | 3.58% |
| 2015 | 353.89 Million USD | 114.6% |
| 2014 | 164.9 Million USD | -7.25% |
| 2013 | 177.8 Million USD | 57629.22% |
| 2012 | 308 Thousand USD | -27.01% |
| 2011 | 422 Thousand USD | 7.38% |
| 2010 | 393 Thousand USD | -79.05% |
| 2009 | 1.87 Million USD | 76.81% |
| 2008 | 1.06 Million USD | -45.78% |
| 2007 | 1.95 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 473.47 Million USD | -4.98% |
| 2024 Q2 | 623.64 Million USD | 31.72% |
| 2023 Q4 | 498.3 Million USD | -7.41% |
| 2023 Q3 | 538.21 Million USD | -12.28% |
| 2023 Q2 | 613.57 Million USD | 48.65% |
| 2023 Q1 | 412.75 Million USD | -0.02% |
| 2023 FY | 498.3 Million USD | 20.7% |
| 2022 Q3 | 412.93 Million USD | -0.02% |
| 2022 Q4 | 412.85 Million USD | -0.02% |
| 2022 FY | 412.85 Million USD | 16.03% |
| 2022 Q1 | 413.08 Million USD | 16.09% |
| 2022 Q2 | 413.01 Million USD | -0.02% |
| 2021 Q3 | 352.14 Million USD | 1.03% |
| 2021 Q1 | 455.94 Million USD | 1.19% |
| 2021 FY | 355.81 Million USD | -21.03% |
| 2021 Q2 | 348.54 Million USD | -23.55% |
| 2021 Q4 | 355.81 Million USD | 1.04% |
| 2020 Q4 | 450.57 Million USD | 1.18% |
| 2020 FY | 450.57 Million USD | 4.77% |
| 2020 Q1 | 435.05 Million USD | 1.16% |
| 2020 Q2 | 440.13 Million USD | 1.17% |
| 2020 Q3 | 445.3 Million USD | 1.17% |
| 2019 FY | 430.07 Million USD | 17.41% |
| 2019 Q2 | 371.41 Million USD | -15.6% |
| 2019 Q3 | 425.33 Million USD | 14.52% |
| 2019 Q4 | 430.07 Million USD | 1.11% |
| 2019 Q1 | 440.03 Million USD | 20.13% |
| 2018 Q4 | 366.29 Million USD | -0.99% |
| 2018 FY | 366.29 Million USD | -7.52% |
| 2018 Q3 | 369.94 Million USD | -2.6% |
| 2018 Q2 | 379.82 Million USD | -2.2% |
| 2018 Q1 | 388.37 Million USD | -1.95% |
| 2017 Q2 | 387.86 Million USD | 1.03% |
| 2017 FY | 396.09 Million USD | 8.05% |
| 2017 Q3 | 391.92 Million USD | 1.05% |
| 2017 Q4 | 396.09 Million USD | 1.06% |
| 2017 Q1 | 383.9 Million USD | 4.73% |
| 2016 FY | 366.57 Million USD | 3.58% |
| 2016 Q3 | 362.8 Million USD | 6.89% |
| 2016 Q4 | 366.57 Million USD | 1.04% |
| 2016 Q1 | 348.83 Million USD | -1.43% |
| 2016 Q2 | 339.4 Million USD | -2.7% |
| 2015 Q3 | 360.25 Million USD | -1.04% |
| 2015 Q4 | 353.89 Million USD | -1.77% |
| 2015 Q1 | 160.42 Million USD | -2.72% |
| 2015 FY | 353.89 Million USD | 114.6% |
| 2015 Q2 | 364.04 Million USD | 126.92% |
| 2014 Q4 | 164.9 Million USD | -1.99% |
| 2014 Q1 | 173.15 Million USD | -2.62% |
| 2014 Q2 | 171.29 Million USD | -1.07% |
| 2014 Q3 | 168.26 Million USD | -1.77% |
| 2014 FY | 164.9 Million USD | -7.25% |
| 2013 Q1 | 174.85 Million USD | 56671.1% |
| 2013 Q4 | 177.8 Million USD | -0.15% |
| 2013 Q3 | 178.07 Million USD | 1.86% |
| 2013 Q2 | 174.82 Million USD | -0.02% |
| 2013 FY | 177.8 Million USD | 57629.22% |
| 2012 Q2 | 364 Thousand USD | -16.32% |
| 2012 Q1 | 435 Thousand USD | 3.08% |
| 2012 Q4 | 308 Thousand USD | -14.68% |
| 2012 Q3 | 361 Thousand USD | -0.82% |
| 2012 FY | 308 Thousand USD | -27.01% |
| 2011 Q4 | 422 Thousand USD | -12.27% |
| 2011 Q2 | 540 Thousand USD | -9.7% |
| 2011 Q1 | 598 Thousand USD | 52.16% |
| 2011 FY | 422 Thousand USD | 7.38% |
| 2011 Q3 | 481 Thousand USD | -10.93% |
| 2010 FY | 393 Thousand USD | -79.05% |
| 2010 Q4 | 393 Thousand USD | -1.75% |
| 2010 Q3 | 400 Thousand USD | -76.68% |
| 2010 Q2 | 1.71 Million USD | 6.99% |
| 2010 Q1 | 1.6 Million USD | -14.55% |
| 2009 Q4 | 1.87 Million USD | -9.46% |
| 2009 Q3 | 2.07 Million USD | 0.0% |
| 2009 FY | 1.87 Million USD | 76.81% |
| 2008 Q4 | 1.06 Million USD | 0.0% |
| 2008 FY | 1.06 Million USD | -45.78% |
| 2007 FY | 1.95 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Cosmos Health Inc. | 3.03 Million USD | -16316.903% |
| Safety Shot Inc | 304.9 Thousand USD | -163329.833% |
| Bright Green Corporation | 201.78 Thousand USD | -246852.915% |
| Embecta Corp. | 1.62 Billion USD | 69.342% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | -60.917% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -447.135% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | -1.704% |
| Dynavax Technologies Corporation | 252.41 Million USD | -97.414% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 0.645% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -3639.374% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 3.014% |
| PainReform Ltd. | 30 Thousand USD | -1660930.0% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -92344.646% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -92344.646% |
| SCYNEXIS, Inc. | 12.15 Million USD | -3998.273% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -425336.058% |
| Journey Medical Corporation | 14.62 Million USD | -3307.94% |
| Alpha Teknova, Inc. | 13.25 Million USD | -3660.539% |
| Procaps Group, S.A. | 28.41 Million USD | -1653.992% |
| Theratechnologies Inc. | 51.26 Million USD | -872.102% |
| Harrow Health, Inc. | 183.17 Million USD | -172.044% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -572668.966% |
| Biofrontera Inc. | 804 Thousand USD | -61878.731% |
| DURECT Corporation | 2.7 Million USD | -18342.228% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1401.112% |
| Cronos Group Inc. | 1.55 Million USD | -31863.374% |
| OptiNose, Inc. | 611 Thousand USD | -81456.301% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1357.47% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -109418.462% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -720.329% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -3797.868% |
| Radius Health, Inc. | 339.66 Million USD | -46.706% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -4757.76% |
| Phibro Animal Health Corporation | 458.28 Million USD | -8.732% |
| Procaps Group S.A. | 28.41 Million USD | -1653.992% |
| Alvotech | 1.02 Billion USD | 51.515% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -7528.735% |
| Viatris Inc. | 16.18 Billion USD | 96.922% |
| Rockwell Medical, Inc. | 8.29 Million USD | -5908.791% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -4481.309% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -148210.223% |
| Tilray Brands, Inc. | 287.93 Million USD | -73.063% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | -313.5% |
| Shineco, Inc. | 10.01 Million USD | -4874.468% |
| PetIQ, Inc. | 437.82 Million USD | -13.816% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -237190.0% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -92.919% |
| Alimera Sciences, Inc. | 64.48 Million USD | -672.704% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | -1193.839% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -368774.594% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -7166.772% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -69109.583% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2216182.69% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -1421.09% |
| Hempacco Co., Inc. | 5.93 Million USD | -8301.769% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 51.515% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -786.418% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 19.122% |
| Currenc Group, Inc. | 2.5 Million USD | -19776.911% |
| Kamada Ltd. | 7.43 Million USD | -6599.503% |
| Indivior PLC | 235.66 Million USD | -111.446% |
| Evoke Pharma, Inc. | 5 Million USD | -9866.18% |
| Flora Growth Corp. | 942 Thousand USD | -52799.045% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2216182.69% |
| Evolus, Inc. | 120.35 Million USD | -314.019% |
| HUTCHMED (China) Limited | 48.18 Million USD | -934.072% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 15.426% |
| Akanda Corp. | 2.49 Million USD | -19855.069% |